6-(4-Methoxyphenyl)-3-pyridazinamine
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
6-(4-Methoxyphenyl)-3-pyridazinamine is a GABAA receptor antagonist.
Ionotropic GABAA receptors are ligand-gated ion channels that facilitate the passing of chloride ions across the cell membrane and promote an inhibitory influence on target neurons. These receptors are the major targets for benzodiazepines and related anxiolytic drugs.
In vitro: 6-(4-Methoxyphenyl)-3-pyridazinamine is an intermediate in the synthesis of SR 95103 [2-(3-carboxypropyl)-3-amino-4-methyl-6-phenylpyridazinium chloride]. SR 95103 was identified as a selective and competitive GABA-A receptor antagonist. Moreover, SR 95103 was shown to be able to displace [3H]GABA from rat brain membranes with an apparent Ki of 2.2 μM. In addition, SR 95103 was found, on the basis of biochemical, electrophysiological, and pharmacological results, to be a selective and competitive antagonist of GABA at the GABA-A receptor site [1].
In vivo: The behavioral effects of unilateral microinjections of SR 95103 into periventricular structures were studied. Results showed that when injected into the medial hypothalamus (MH) or into the dorsal part of the mesencephalic central gray (CG), SR 95103 produced a dose-dependent behavioral activation together with jumps. The behavioral activation was found to be attenuated by pretreatment with THIP, a GABA receptor agonist [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Wermuth, C. G.,Bourguignon, J.J.,Schlewer, G., et al. Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of γ-aminobutyric acid acting as selective GABA-A antagonists. Journal of Medicinal Chemistry 30(2), 239-249 (1987).
[2] Schmitt P, Di Scala G, Brandao ML, Karli P. Behavioral effects of microinjections of SR 95103, a new GABA-A antagonist, into the medial hypothalamus or the mesencephalic central gray. Eur J Pharmacol. 1985 Nov 5;117(2):149-58.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 201.2 |
Cas No. | 4776-87-8 |
Formula | C11H11N3O |
Solubility | ≤10mg/ml in ethanol;15mg/ml in DMSO;10mg/ml in dimethyl formamide |
Chemical Name | 6-(4-methoxyphenyl)-3-pyridazinamine |
SDF | Download SDF |
Canonical SMILES | NC1=NN=C(C2=CC=C(OC)C=C2)C=C1 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |